ReWalk Robotics

ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Yokneam Ilit, Israel.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass., June 22, 2020 /PRNewswire/ -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced the publication of the results of its multi-center clinical study of...

ReWalk Announces Publication of ReStore Powered Exo-Suit Clinical Study Results

-- Additional Lines Expand Company’s Portfolio and Include Telehealth Capable Stroke Rehabilitation Devices as well as Clinic and Home Use Devices for Persons with Spinal Cord Injury -- MARLBOROUGH, Mass., June  04, 2020  (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk," “we” or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, has finalized and moved to implement two separate agreements to distribute additional product lines in the United States market. Upon commencement of the effective periods of these agreements, the Company will be the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States, and will also have distribution rights for the MYOLYN MyoCycle Functional Electrical Stimulation (“FES”) cycles to U.S. rehabilitation clinics and personal sales through the U.S. Department of Veterans Affairs (“VA”) hospitals.

ReWalk Robotics Finalizes U.S. Distribution Agreements for Two Additional Neuro Rehabilitation Product Lines

ReWalk Robotics (RWLK) news for Monday includes RWLK stock soaring higher on FDA approval for one of its powered exoskeletons.
The post ReWalk Robotics News: RWLK Stock Rockets 31% on FDA Approval appeared first on InvestorPlace.

ReWalk Robotics News: RWLK Stock Rockets 31% on FDA Approval

ReWalk Robotics' (RWLK) CEO Larry Jasinski on Q1 2020 Results - Earnings Call Transcript

Shares of ReWalk Robotics (NASDAQ:RWLK) moved higher by 2.4% in pre-market trading after the company reported Q1 results.

Recap: ReWalk Robotics Q1 Earnings

— Q1 2020 Total Revenue of $0.8 million at a reduced level due to COVID-19 pandemic —

ReWalk Robotics Reports First Quarter 2020 Financial Results

Since hitting a low in early April, ReWalk shares have tripled in value.

ReWalk Robotics: Quietly Building Momentum, But Facing Long Odds

ReWalk (RWLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will ReWalk Robotics (RWLK) Report Negative Q1 Earnings? What You Should Know

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, March  24, 2020  (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) a global leader in Exoskeleton technology for community use and rehabilitation centers, today issued the following letter to shareholders:

ReWalk Letter to Shareholders on COVID-19 and the Potential Impact on Operations

ReWalk Robotics Ltd. (RWLK) CEO Larry Jasinski on Q4 2019 Results - Earnings Call Transcript

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Feb.  10, 2020  (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ ReWalk ” or the “ Company ”) today announced the closing and funding of its previously announced public offering of 4,053,172 units at a price to the public of $1.25 per unit and 1,546,828 pre-funded units at a price to the public of $1.249 per pre-funded unit. The gross proceeds of from the offering, before deducting placement agent fees and offering expenses, are $7.0 million.

ReWalk Robotics Announces Closing of $7.0 Million Public Offering

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Feb.  06, 2020  (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ ReWalk ” or the “ Company ”) today announced the pricing of a public offering of 5,600,000 units at a price to the public of $1.25 per unit, for gross proceeds of $7.0 million, before deducting placement agent fees and other estimated offering expenses payable by ReWalk. Each unit contains one ordinary share (or ordinary share equivalent) and one common warrant to purchase one ordinary share. The ordinary shares (or ordinary share equivalents) and common warrants included in the units can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about February 10, 2020, subject to customary closing conditions.

ReWalk Robotics Announces Pricing of $7.0 Million Public Offering

Alexion Pharma

Civeo

Integer Holdings

OpGen

What bargain hunting? Stocks with a rising P/E can also be worth buying too.

Adopt Rising P/E Technique With These 5 Top-Ranked Stocks

ReWalk Robotics Ltd. (RWLK) CEO Larry Jasinski on Q3 2019 Results - Earnings Call Transcript

ReWalk (RWLK) delivered earnings and revenue surprises of -2.22% and -62.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ReWalk Robotics (RWLK) Reports Q3 Loss, Misses Revenue Estimates

ReWalk Robotics (RWLK) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Sept.  23, 2019  (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief Executive Officer, will present at the Sidoti & Company Conference in New York City as follows:

ReWalk Robotics to Present at the Sidoti & Company Conference on September 25th

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Aug.  23, 2019  (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief Executive Officer and Ori Gon Chief Financial Officer, will present at the H.C.WAINWRIGHT Conference in New York City as follows:

ReWalk Robotics to Present at the H.C. WAINWRIGHT Conference on September 9th

When I wrote my very first piece for Seeking Alpha about the Israeli nano-cap medical technology company ReWalk (RWLK) back in March 2016, I was addressing the introduction of more competition into the space for its only product at the time, an exoskeleton suit used primary to assist those with spinal cord injury be able to walk again.

ReWalk Robotics: Taking The Next Steps

Rewalk Robotics Ltd. (RWLK) CEO Lawrence Jasinski on Q2 2019 Results - Earnings Call Transcript

ReWalk (RWLK) delivered earnings and revenue surprises of -79.59% and -64.57%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ReWalk Robotics (RWLK) Reports Q2 Loss, Lags Revenue Estimates

Shares of ReWalk Robotics Ltd.  tumbled 21% to pace all Nasdaq losers, after the maker of wearable robotic exoskeletons for use by people with limb disabilities announced a stock offering to rate about $5 million.

ReWalk stock tumbles after company follows recent price surge with share sales

ReWalk Robotics exo-suit news for Wednesday has RWLK stock heading into orbit thanks to approval from the FDA for one of its devices.
The post ReWalk Robotics Exo-Suit News: RWLK Stock Skyrockets on FDA Approval appeared first on InvestorPlace.

ReWalk Robotics Exo-Suit News: RWLK Stock Skyrockets on FDA Approval

Shares of ReWalk Robotics Ltd.  rocketed 176% in very active premarket trading Wednesday, after the Food and Drug Administration cleared the company's ReStore soft exo-suit system for sale to rehabilitation centers.

ReWalk's stock nearly triples after FDA clears ReStore for sale in rehab centers

Shares of nanocap medical device company Rewalk Robotics Ltd (NASDAQ: RWLK) soared in pre-market trading Wednesday.

News for ReWalk Robotics Stock (RWLK)